Compare ACADIA Pharmaceuticals Inc. (ACAD) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs DexCom, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while DexCom, Inc. trades at $73.27 (market cap $28.39B). The key difference: DexCom, Inc. is far larger — about 6.3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | DXCM | |
|---|---|---|
Market Cap | $4.49B | $28.39B |
Sector | Health | Health |
52-Week High | $28.06 | $89.53 |
52-Week Low | $20.06 | $54.84 |
Enterprise Value | $3.69B | $27.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DXCM trades at $73.57, up 3.26% with a bullish technical outlook and strong fundamental performance. Recent earnings beats and FDA clearances for pediatric use of Stelo CGM support growth. Revenue reached $4.66B in 2025 with net income of $836.30M, reflecting a 19.31% margin. Analyst consensus is strongly bullish with an $83.78 price target.
The outlook remains positive driven by CGM market expansion and international growth, though risks include GLP-1 drug competition and execution in non-insulin markets. Valuation at 31.06 P/E is reasonable for its growth profile, with institutional sentiment favoring further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
